IVERIC bio (ISEE) Osake Kurssi

Iveric Bio Inc is primarily active in the biotechnology industry.

The main competitors of Iveric Bio Inc in the market include Genentech, Regeneron Pharmaceuticals, and Novartis.

Iveric Bio Inc is a biopharmaceutical company specializing in the discovery and development of novel therapies for retinal diseases. Founded in 2014, the company is headquartered in New York City, USA. Iveric Bio focuses on innovative treatments for conditions such as age-related macular degeneration (AMD) and orphan inherited retinal diseases. They have a strong commitment to advancing therapies that could potentially improve the lives of patients with vision loss. With a diverse pipeline of investigational drug candidates, Iveric Bio continues to contribute to the advancement of ophthalmic research and strives to become a leader in the field of retinal disease therapeutics.

Some significant milestones achieved by Iveric Bio Inc include the successful completion of Phase 3 clinical trials for Zimura, their leading investigational therapy for geographic atrophy, a form of age-related macular degeneration (AMD). The company has also received Fast Track designation from the U.S. FDA for Zimura in this indication. Additionally, Iveric Bio Inc has secured patents for novel technologies and treatment approaches related to retinal diseases. These achievements highlight the company's commitment to advancing innovative therapies for patients with AMD and other retinal disorders.

Iveric Bio Inc is primarily present in the United States.

Iveric Bio Inc represents values of innovation, commitment, and excellence in the biopharmaceutical industry. With a strong corporate philosophy focused on developing novel therapies for ophthalmic diseases, Iveric Bio Inc aims to improve the lives of patients worldwide. The company's dedicated research and development efforts prioritize advancing treatments for vision-threatening conditions, such as age-related macular degeneration and inherited retinal diseases. Iveric Bio Inc's commitment to cutting-edge technologies, strategic partnerships, and a patient-centric approach underscores its mission to address unmet medical needs and deliver impactful solutions in the field of eye care.

14 analyytikkoa arvioi tällä hetkellä IVERIC bio-osaketta: 0 suosittaa ostoa, 11 pitoa ja 3 myyntiä.

IVERIC bio Analyytikkojen kursstavoitteet 2026

IVERIC bio-osake (ISEE) on listattuna 5 pörssissä, muun muassa: NASDAQ (ISEE), SIX (Zürich) (O2T.SW), Frankfurt (O2T.F), München (O2T.MU), Düsseldorf (O2T.DU).

Iveric Bio Inc. is a US-based company specializing in the development and marketing of novel therapeutics for various eye diseases. The company was founded in 2019 by spinning off from the existing company Ophthotech, which took over the research and development for Iveric Biopharma. The business model of Iveric Bio Inc. revolves around the research, development, and marketing of therapeutics focusing on various eye diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and geographic atrophy (GA). AMD is the leading cause of blindness in older individuals in developed countries, while DR and GA are considered common complications in diabetic patients. The company is divided into three main divisions. The first division focuses on the development of novel therapeutic agents for various eye diseases. This division advances various preparations, including Zimura (avacincaptad pegol), which is a new class of medication for AMD treatment. This preparation aims to inhibit a specific component, Complement Factor C5, which plays a key role in the immune system functioning in the retina and causes inflammation. The second division of Iveric Bio Inc.'s business model relates to the licensing of technologies aimed at the discovery and development of new therapeutics for various eye diseases. Kyverstis is the company's main licensing program, concentrating on the preclinical development of novel therapeutics for AMD, diabetic retinopathy, and GA. The third division of Iveric Bio Inc. is the 'EIGENKAPITAL KOMPLEMENT' program. This initiative uses new technologies to study cellular processes in the retina with the goal of gaining new insights into AMD development. The program aims to acquire knowledge that can contribute to the development of future therapeutics and better help patients. The company's business activities are strengthened through partnerships and collaborations, enabling Iveric Bio Inc. to advance its research, development, and marketing of products and technologies. For example, the company collaborates with leading biotechnology company Regeneron Pharmaceuticals to advance its ongoing research and development programs. Overall, Iveric Bio Inc. offers a comprehensive portfolio of innovative therapeutics, technologies, and services for the treatment of eye diseases. The company constantly strives to further develop its products and technologies to better meet the needs of patients.

Liikevaihtoa ei voida laskea IVERIC bio:lle tällä hetkellä.

Voittoa ei voida laskea IVERIC bio:lle tällä hetkellä.

P/E-suhdetta ei voida laskea IVERIC bio:lle tällä hetkellä.

P/S-suhdetta ei voida laskea IVERIC bio:lle tällä hetkellä.

IVERIC bio:n Eulpool-laatuscore on 2/10.

IVERIC bio:n ISIN on US46583P1021. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

IVERIC bio:n WKN on A2PHLF. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

IVERIC bio:n ticker on ISEE. Tämä pörssinoteeraus käytetään IVERIC bio-osakkeiden kauppaan pörssissä.